[Ser25] Protein Kinase C (19-31) Mechanism, Clinical Value,

[Ser25] Protein Kinase C (19-31): Mechanism, Clinical Value, and Research Applications

Introduction
[Ser25] Protein Kinase C (19-31) is a synthetic peptide corresponding to amino acids 19-31 of the protein kinase C (PKC) substrate, with a serine residue phosphorylated at position 25. This peptide is widely utilized as a substrate in kinase assays to measure PKC activity in vitro, providing a robust and specific tool for biochemical and pharmacological research. The sequence of [Ser25] PKC (19-31) is Ac-RFARKGSLRQKNV-NH2, where the serine at position 25 is phosphorylated, mimicking the phosphorylated state of endogenous PKC substrates.

Protein kinase C is a family of serine/threonine kinases that play pivotal roles in signal transduction pathways, regulating diverse cellular processes such as proliferation, differentiation, apoptosis, and immune responses (Newton, 2018, J Biol Chem). Aberrant PKC activity is implicated in numerous pathological conditions, including cancer, cardiovascular diseases, and neurological disorders. The [Ser25] PKC (19-31) peptide serves as a valuable research tool for dissecting PKC-mediated signaling mechanisms and for screening potential PKC modulators.

[Related: trichostatin-a] Mechanistically, [Ser25] PKC (19-31) acts as a competitive substrate for PKC isoforms. Upon incubation with active PKC and ATP, the peptide undergoes phosphorylation, which can be quantitatively measured using various detection methods such as radiometric, colorimetric, or fluorescence-based assays. This enables precise assessment of PKC activity and the evaluation of PKC-targeting compounds in drug discovery pipelines.

Clinical Value and Applications
The clinical value of [Ser25] PKC (19-31) lies in its utility as a research reagent for elucidating PKC function and for screening PKC inhibitors or activators. Given the central role of PKC in disease pathogenesis, accurate measurement of PKC activity is critical for both basic research and translational applications. For example, PKC isoforms have been identified as therapeutic targets in oncology, where their dysregulation contributes to tumor growth, metastasis, and resistance to therapy (Griner & Kazanietz, 2007, Nat Rev Cancer).

[Related: exendin-4 antibody] In cardiovascular research, PKC modulates cardiac contractility, vascular tone, and myocardial remodeling, making it a target for heart failure and hypertension interventions (Steinberg, 2008, Circ Res). In neurology, PKC signaling is implicated in synaptic plasticity, neuroprotection, and neurodegeneration, with relevance to conditions such as Alzheimer’s disease and stroke (Sun & Alkon, 2014, Front Pharmacol). The [Ser25] PKC (19-31) peptide enables high-throughput screening of small molecule libraries for PKC modulators, facilitating the identification of candidate therapeutics.

Moreover, the peptide is employed in kinase profiling assays to assess the selectivity and potency of investigational drugs, supporting lead optimization and safety evaluation in preclinical development. Its defined sequence and phosphorylation site confer specificity, reducing background noise and increasing assay reliability.

[Related: hdac inhibitor tsa] Key Challenges and Pain Points Addressed
Traditional approaches to measuring PKC activity, such as whole-cell lysate assays or endogenous substrate phosphorylation, often suffer from low specificity, interference from other kinases, and variable reproducibility. These limitations hinder the accurate characterization of PKC function and the development of selective PKC-targeting drugs.

[Ser25] PKC (19-31) addresses these challenges by providing a defined, synthetic substrate that is selectively recognized and phosphorylated by PKC isoforms. Its use minimizes cross-reactivity with other kinases, enabling more precise quantification of PKC activity. Additionally, the peptide’s compatibility with multiple detection platforms (e.g., radiometric, ELISA, fluorescence) allows for flexible assay design and adaptation to high-throughput screening formats.

Another pain point in PKC research is the need to distinguish between different PKC isoforms, which have overlapping but distinct biological functions. By optimizing assay conditions and using isoform-specific inhibitors or activators in conjunction with [Ser25] PKC (19-31), researchers can dissect isoform-specific signaling pathways, informing the rational design of targeted therapies.

Literature Review
Numerous studies have validated the utility of synthetic PKC substrate peptides, including [Ser25] PKC (19-31), in kinase assays and drug discovery workflows:

1. **Newton, A.C. (2018). Protein kinase C: perfectly balanced. J Biol Chem, 293(44), 17817-17830.**
This review highlights the structural and functional diversity of PKC isoforms, emphasizing the need for specific substrates in biochemical assays to accurately measure PKC activity.

2. **Griner, E.M., & Kazanietz, M.G. (2007). Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer, 7(4), 281-294.**
The authors discuss the role of PKC in oncogenic signaling and the importance of reliable PKC activity assays for identifying novel anticancer agents.

3. **Steinberg, S.F. (2008). Structural basis of protein kinase C isoform function. Physiol Rev, 88(4), 1341-1378.**
This comprehensive review describes the molecular mechanisms of PKC regulation and the application of synthetic peptides in functional studies.

4. **Sun, M.K., & Alkon, D.L. (2014). The "memory kinases": roles of PKC isoforms in signal processing and memory formation. Front Pharmacol, 5, 23.**
The study explores the involvement of PKC in neuronal signaling and memory, underscoring the value of substrate peptides in neuropharmacological research.

5. **Cohen, P. (2000). The regulation of protein function by multisite phosphorylation—a 25 year update. Trends Biochem Sci, 25(12), 596-601.**
Cohen reviews the principles of kinase substrate recognition and the development of synthetic peptides for kinase assays.

6. **Basu, A., & Sivaprasad, U. (2007). Protein kinase Cε makes the life and death decision. Cell Signal, 19(8), 1633-1642.**
This article discusses the isoform-specific roles of PKC in apoptosis and the use of peptide substrates to study these processes.

7. **Mochly-Rosen, D., & Das, K. (2012). Pharmacological targeting of protein kinase C. Trends Pharmacol Sci, 33(8), 474-484.**
The authors review the challenges in developing PKC modulators and the necessity of robust assay systems using synthetic substrates.

Collectively, these studies establish the scientific foundation for the use of [Ser25] PKC (19-31) in PKC research and drug discovery.

Experimental Data and Results
Experimental validation of [Ser25] PKC (19-31) as a PKC substrate has been demonstrated in multiple studies. For example, radiometric kinase assays using [γ-32P] ATP and [Ser25] PKC (19-31) have shown robust, dose-dependent phosphorylation by conventional and novel PKC isoforms, with minimal background from unrelated kinases (Newton, 2018, J Biol Chem). The kinetic parameters (Km and Vmax) for PKC-mediated phosphorylation of the peptide are consistent with those observed for endogenous substrates, supporting its physiological relevance.

In high-throughput screening campaigns, [Ser25] PKC (19-31) has enabled the identification of selective PKC inhibitors with nanomolar potency. For instance, Griner & Kazanietz (2007, Nat Rev Cancer) reported the use of synthetic PKC substrate peptides in screening libraries of small molecules, leading to the discovery of novel chemotypes with anti-proliferative activity in cancer cell lines.

Fluorescence-based assays using labeled [Ser25] PKC (19-31) derivatives have further improved assay sensitivity and throughput, facilitating large-scale profiling of kinase inhibitor selectivity (Mochly-Rosen & Das, 2012, Trends Pharmacol Sci). These data underscore the peptide’s utility in both basic and applied research settings.

Usage Guidelines and Best Practices
To maximize the reliability and reproducibility of PKC activity assays using [Ser25] PKC (19-31), the following guidelines are recommended:

1. **Peptide Preparation:** Reconstitute the lyophilized peptide in sterile water or assay buffer to the desired concentration. Aliquot and store at -20°C to avoid repeated freeze-thaw cycles.

2. **Assay Buffer:** Use a buffer system optimized for PKC activity, typically containing Tris-HCl (pH 7.5), MgCl2, CaCl2, and phosph Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 52 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11536852